Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date
Thomas Whitfield, Adele Torkington, Clare van Halsema North West Infectious Diseases Unit, North Manchester General Hospital, Manchester, UK Abstract: Modern antiretroviral therapy has demonstrated effectiveness in preexposure prophylaxis (PrEP) and treatment of HIV infection. There is a demand for...
Guardado en:
Autores principales: | Whitfield T, Torkington A, van Halsema C |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8204d9e6384e4f53af6f4a9c61f4bc63 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
por: Fernandez C, et al.
Publicado: (2019) -
Profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date
por: Hill L, et al.
Publicado: (2018) -
EXPERIENCE WITH DOLUTEGRAVIR IN HIV PATIENTS AT A PUBLIC SECTOR HOSPITAL IN KARACHI, PAKISTAN
por: Farzana Batool, et al.
Publicado: (2021) -
Pre-Exposure Prophylaxis (PrEP) in the Prevention of HIV: Strategies, Target Populations and Upcoming Treatments
por: Özdener-Poyraz AE, et al.
Publicado: (2020) -
Reversal of Epigenetic Silencing Allows Robust HIV-1 Replication in the Absence of Integrase Function
por: Ishak D. Irwan, et al.
Publicado: (2020)